London-listed AstraZeneca, known for its treatments for cancer, diabetes, and Covid-19, will invest $50 billion in U.S. facilities.

In all, the company expects to have lost as much as $2.7 billion over the first half of 2025 as a result of costly efforts to improve profitability and tariff-related expenses. The losses also include compliance charges with Trump’s suspension of financial penalties tied to fuel emissions standards.